Adaptive Biotechnologies Corp - ESG Rating & Company Profile powered by AI
This ESG rating for Adaptive Biotechnologies Corp indicates its transparency towards the United Nations SDGs. If you work at Adaptive Biotechnologies Corp and you would like to use your Sustainability rating, please contact us. The webpage contains a free E,S&G assessment for Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.8; made up of an environmental score of 2.7, social score of 4.6 and governance score of 4.0.
3.8
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1089 | Zymeworks Inc | 3.9 | Medium |
1089 | bluebird bio Inc | 3.9 | Medium |
1112 | Adaptive Biotechnologies Corp | 3.8 | Medium |
1112 | AcelRx Pharmaceuticals Inc | 3.8 | Medium |
1112 | Arcus Biosciences Inc | 3.8 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Adaptive Biotechnologies Corp have an accelerator or VC vehicle to help deliver innovation?
Does Adaptive Biotechnologies Corp disclose current and historical energy intensity?
Does Adaptive Biotechnologies Corp report the average age of the workforce?
Does Adaptive Biotechnologies Corp reference operational or capital allocation in relation to climate change?
Does Adaptive Biotechnologies Corp disclose its ethnicity pay gap?
Does Adaptive Biotechnologies Corp disclose cybersecurity risks?
Does Adaptive Biotechnologies Corp offer flexible work?
Does Adaptive Biotechnologies Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Adaptive Biotechnologies Corp disclose the number of employees in R&D functions?
Does Adaptive Biotechnologies Corp conduct supply chain audits?
Does Adaptive Biotechnologies Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Adaptive Biotechnologies Corp conduct 360 degree staff reviews?
Does Adaptive Biotechnologies Corp disclose the individual responsible for D&I?
Does Adaptive Biotechnologies Corp disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Adaptive Biotechnologies Corp disclose current and / or historical scope 2 emissions?
Does Adaptive Biotechnologies Corp disclose water use targets?
Does Adaptive Biotechnologies Corp have careers partnerships with academic institutions?
Did Adaptive Biotechnologies Corp have a product recall in the last two years?
Does Adaptive Biotechnologies Corp disclose incidents of discrimination?
Does Adaptive Biotechnologies Corp allow for Work Councils/Collective Agreements to be formed?
Has Adaptive Biotechnologies Corp issued a profit warning in the past 24 months?
Does Adaptive Biotechnologies Corp disclose parental leave metrics?
Does Adaptive Biotechnologies Corp disclose climate scenario or pathway analysis?
Does Adaptive Biotechnologies Corp disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Adaptive Biotechnologies Corp disclose the pay ratio of women to men?
Does Adaptive Biotechnologies Corp support suppliers with sustainability related research and development?
Does Adaptive Biotechnologies Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Adaptive Biotechnologies Corp reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Adaptive Biotechnologies Corp involved in embryonic stem cell research?
Does Adaptive Biotechnologies Corp disclose GHG and Air Emissions intensity?
Does Adaptive Biotechnologies Corp disclose its waste policy?
Does Adaptive Biotechnologies Corp report according to TCFD requirements?
Does Adaptive Biotechnologies Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Adaptive Biotechnologies Corp disclose energy use targets?
Does Adaptive Biotechnologies Corp disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Adaptive Biotechnologies Corp have a policy relating to cyber security?
Have a different question?
Potential Risks for Adaptive Biotechnologies Corp
These potential risks are based on the size, segment and geographies of the company.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.